Sword Bio
Private Company
Total funding raised: $4.8M
Overview
Sword Bio is a specialized bioanalytical Contract Research Organization (CRO) founded in 2020 and headquartered in San Francisco. The company leverages a team of scientists with decades of experience to offer rapid, customized assay development and testing services under various regulatory standards (non-GLP, GLP, GCP). Its core business model is providing essential laboratory services to accelerate the drug development pipelines of its biopharma clients, utilizing an 'excess capacity' operational model to ensure quick project initiation and turnaround.
Technology Platform
Integrated suite of bioanalytical techniques including Ligand Binding Assays (LBA), qPCR/dPCR, cell-based assays, and MSD immunoassays for pharmacokinetics, immunogenicity, and biomarker analysis. Offers a 'Sword SWIFT' program for assay optimization.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Operates in the highly competitive bioanalytical CRO sector, competing against large, full-service CROs (e.g., LabCorp, IQVIA) and numerous specialized boutique labs. Differentiation is based on scientific expertise, rapid project initiation ('excess capacity' model), and a flexible, partnership-driven client service approach.